Weekly Report on China's Health Industry: SJTU Medical Robotics Empowered by Ten Centers; Maicim Critical Care AI Model Launched by Maixing Medical!

Empowered by Ten Centers, SJTU Medical Robotics

The Medical Robotics Research Institute of Shanghai Jiao Tong University (hereinafter referred to as "the Institute") has explored the field of surgical robotics for five years, paving an innovative path that few have taken. Since its establishment, the Institute has fully integrated the medical-engineering interdisciplinary teams of Shanghai Jiao Tong University to conduct cutting-edge technology research and clinical applications. It has also collaborated with several high-level research hospitals in Shanghai, establishing clinical joint research centers based on the hospitals' specialized disciplines to promote clinical translation. Additionally, it fosters the clinical translation of innovative robotic technologies through multidisciplinary talent cultivation and industrial incubation bases, further promoting the organic integration of the medical robotics technology innovation chain with clinical applications and the industrial chain. (Source: Arterial Network)

PulseMed Critical Care Large Model Released!

On December 19, 2024, Hangzhou Maicim Medical Technology Co., Ltd. (referred to as: Maicim Medical) joined forces with Zhejiang Hospital to launch their independently developed critical care specialty large model — Maicim®1.0. Professor Hu Weihang, Director of the Department of Critical Care Medicine at Zhejiang Hospital, stated: This model attempts to utilize AI to process the massive, multi-modal data generated in the ICU, and through deep analysis and mining, extract the most essential core information needed by medical staff, achieving streamlined data and comprehensive evaluation, thereby assisting the medical team in gaining an advantage in the race against death. (Source: Arterial Network)

$14.6 Billion: Lianyungang’s Small Molecule Drug Sells for Sky-High Price!

On December 18, 2024, Hansoh Pharma and Merck jointly announced that they had signed a global exclusive licensing agreement for HS-10535 (an investigational oral small-molecule GLP-1 receptor agonist). Under the agreement, Hansoh Pharma grants Merck the global exclusive rights to develop, manufacture, and commercialize HS-10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive milestone payments of up to $1.9 billion based on the development, regulatory approval, and commercialization progress of the candidate drug. Additionally, Hansoh Pharma will also receive royalties based on product sales (total cooperation amounting to up to $2.012 billion, approximately RMB 14.66 billion). Under specific conditions, Hansoh Pharma may co-promote or exclusively commercialize HS-10535 in China. (Source: Arterial Network)

$6.2 Billion: Another Chinese Pharmaceutical Company Sells Its Pipeline

On December 20, WuXi Biologics and DuoXi Biologics jointly announced a research service collaboration agreement with Aadi Bioscience. Through this partnership, Aadi will obtain the global exclusive rights for the development, manufacturing, and commercialization of three ADC drugs at the preclinical stage. According to the terms of the agreement, Aadi will pay WuXi Biologics and DuoXi Biologics an upfront payment of $44 million, up to $265 million in development milestone payments, $540 million in commercial milestone payments, and single-digit percentage royalties on sales. The total value of the collaboration could reach $849 million, approximately RMB 6.2 billion. (Source: Arterial Network)

Vickor Successfully Closes Series C Financing

Recently, Wuhan Vickor Medical Technology Co., Ltd. ("Vickor") officially announced that it has successfully completed its Series C financing round, raising hundreds of millions of RMB. The round was fully led by Bohua Capital, a well-known investment institution in Liangxi District, Wuxi City. This financing will provide strong financial support for Vickor in areas such as product development, market expansion, and international strategic layout. (Source: Menet)

3D Medicines' Pathology AI Platform "Shuda Technology" Completes Nearly RMB 10 Million Angel Round Financing

Recently, 3D Medicines Diagnostics' pathology AI platform —— Shanghai Shuda Data Technology Co., Ltd. (hereinafter referred to as "Shuda Technology") —— has completed its angel round of financing, securing nearly RMB 10 million in funding. This round was led by Muhua Innovation, with participation from Shanghai Lanshang Tingxiu Technology Service Co., Ltd. (hereinafter referred to as "Lanshang Tingxiu") and Shanghai Tongyang Private Equity Investment Fund Partnership (Limited Partnership) (hereinafter referred to as "Tongyang Fund"). The funds will be invested in the research and development and commercial operations of Shuda Technology's related products, injecting strong momentum into the continuous transformation of innovative achievements. (Source: Menet)

Chentai New Materials Completes Over 100 Million Yuan in Equity Financing

Suzhou Chentai New Material Technology Co., Ltd. (hereinafter referred to as "Chentai New Material"), announced the completion of an equity financing round exceeding 100 million yuan. This round of financing was led by Vivo Capital, with funds managed by CICC Capital participating, and WinX Capital serving as the exclusive financial advisor. The proceeds from this round will be used for production line construction and subsequent product iteration research and development. (Source: Menet)

ZhiTong Technology Completes Nearly 100 Million Yuan in Series A Financing

Recently, Jiaxing Zhitong Technology Co., Ltd. (hereinafter referred to as "Zhitong Technology") announced the completion of a nearly 100-million-yuan Series A round of financing. This round of financing was jointly led by Aibo Qing Shi Fund and Shanlan Capital, with participation from Zero One Ventures, Chongqing Airuilin, and WinX Capital serving as the exclusive financial advisor for this transaction while continuing to oversee subsequent financing. The funds from this round of financing will be mainly used for the research and development, registration, and market promotion of surgical and ophthalmic modular products as well as the complete system of microscopic surgical endoscopes. The introduction of numerous investors with industrial resources from ophthalmic listed companies in this round of financing reflects the high recognition of the industry for Zhitong Technology. (Source: Menet)

Yangtze River Pharmaceutical Product Pipeline Progresses Continuously, Multiple Products in Submission Sprint

So far this year, Yangtze River Pharmaceutical has seen continuous progress in its product pipeline: 15 varieties have been approved for production and are considered to have passed the quality evaluation, while six varieties have been submitted for production under the new registration classification. Currently, the company has 169 varieties that have passed or are considered to have passed the quality evaluation (37 of which are first or exclusive), 51 varieties selected in national centralized procurement, multiple varieties achieving significant sales growth, and 17 varieties preparing for the tenth round of centralized procurement. In the R&D pipeline, 23 new drugs are at the stage of clinical application or above, five new drugs are approaching market launch, and 30 generic drugs have been submitted for review under the new registration classification. (Source: Menet)

Zhejiang 5th Batch Centralized Procurement Intended Selection Public Announcement

Recently, the Zhejiang Provincial Medical Insurance Bureau issued the "Announcement on the Tentative Winning Results of the Fifth Batch of Drug Centralized Volume Procurement in Public Medical Institutions in Zhejiang Province," disclosing the tentative winning results of the fifth batch of drug procurement in the province. The announcement period lasts for 7 working days from the date of issuance. The announcement lists 78 tentative winning varieties, including 50 chemical drugs and 28 traditional Chinese medicine specifications. The fifth batch of procurement in Zhejiang adopted a comprehensive review method for evaluation, so the announcement also disclosed the detailed technical scoring table. (Source: Menet)